IKT Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 55.80%

Insider Buying (Last 12 Months): $17,426.72

Insider Selling (Last 12 Months): $0.00

Inhibikase Therapeutics Insider Trading History Chart

Inhibikase Therapeutics Share Price & Price History

^$0.49

▼ -0.01 (-2.00%)

As of 12/9/2022 01:00 AM ET

Days: 30 | 90 | 365

Nobel Prize Winner's Premonition About Nuclear Energy Comes True

From Investing Trends | Ad

Nobel Prize-winning physicist Dr. Burton Richter made a controversial statement 15 years ago. Despite skepticism, he predicted that more nuclear power was needed to help combat the damaging effects of a changing climate.

As it turns out, he was correct... Experts now advise that nuclear power is the ONLY realistic way for the world to meet climate goals and achieve energy independence.

Will This Nuclear Revival Send Uranium A Bull Run?

Inhibikase Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/16/2022	Milton H. Werner	CEO	Buy	5,000	$0.80	$4,000.00	5,335,433
5/27/2022	Milton H. Werner	CEO	Buy	5,000	$0.98	$4,900.00	5,330,433
5/20/2022	Milton H. Werner	CEO	Buy	10,000	$0.60	$6,000.00	5,325,433
5/19/2022	Joseph Frattaroli	CFO	Buy	3,948	$0.64	$2,526.72	48,091
11/17/2021	Milton H. Werner	CEO	Buy	23,589	$1.97	$46,470.33

Nobel Prize Winner's Premonition About Nuclear Energy Comes True

From Investing Trends | Ad

Will This Nuclear Revival Send Uranium A Bull Run?

SEC Filings (Institutional Ownership Changes) for Inhibikase Therapeutics (NYSE:IKT)

13.29% of Inhibikase Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Inhibikase Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/14/2022	Renaissance Technologies LLC	124,683	$0.11M	0.0%	-43.8%	0.494%
8/13/2022	Renaissance Technologies LLC	221,900	$0.17M	0.0%	+17.7%	0.880%
7/12/2022	Koshinski Asset Management Inc.	65,377	$49K	0.0%	N/A	0.259%
5/13/2022	Vanguard Group Inc.	530,098	$0.79M	0.0%	+10.7%	2.101%
5/6/2022	Retirement Planning Co of New England Inc.	116,402	$0.17M	0.1%	-21.0%	0.461%
5/5/2022	Lynwood Capital Management Inc.	120,000	$0.18M	0.2%	-52.9%	0.476%
5/4/2022	Hamilton Lane Advisors LLC	165,635	$0.25M	0.1%	N/A	0.657%
5/3/2022	Redmond Asset Management LLC	122,682	$0.18M	0.1%	N/A	0.486%
2/14/2022	Murchinson Ltd.	220,947	$0.33M	0.0%	-31.2%	0.878%
2/8/2022	Retirement Planning Co of New England Inc.	147,331	$0.22M	0.1%	N/A	0.586%
2/3/2022	ACT Capital Management LLC	1,076,500	$1.58M	1.1%	+6.6%	4.279%
11/16/2021	ACT Capital L.L.C.	1,010,000	$1.92M	1.0%	+15.4%	4.019%
11/16/2021	Warberg Asset Management LLC	26,000	$49K	0.0%	-71.1%	0.103%
11/9/2021	BlackRock Inc.	50,741	$96K	0.0%	+273.9%	0.202%
8/17/2021	Zeke Capital Advisors LLC	93,800	$0.26M	0.0%	+398.9%	0.926%
8/16/2021	Antara Capital LP	250,000	$0.70M	0.0%	N/A	2.467%
8/16/2021	Warberg Asset Management LLC	90,000	$0.25M	0.0%	N/A	0.888%
8/16/2021	Sabby Management LLC	421,200	$1.18M	0.2%	N/A	4.157%
8/13/2021	Altium Capital Management LP	109,749	$0.31M	0.1%	N/A	1.083%
8/13/2021	Murchinson Ltd.	320,947	$0.90M	0.3%	N/A	3.167%
8/13/2021	Vanguard Group Inc.	470,615	$1.32M	0.0%	N/A	4.644%
8/13/2021	FMR LLC	433,300	$1.21M	0.0%	+333.3%	4.276%
8/12/2021	Kepos Capital LP	700,000	$1.96M	0.1%	N/A	6.908%
5/21/2021	Citadel Advisors LLC	17,857	$0.11M	0.0%	N/A	0.178%
5/18/2021	Millennium Management LLC	11,224	$67K	0.0%	N/A	0.112%
5/18/2021	Citadel Advisors LLC	17,857	$0.11M	0.0%	N/A	0.178%
5/17/2021	HRT Financial LP	11,614	$69K	0.0%	N/A	0.115%

Data available starting January 2016

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Today's Range

Now: $0.49

$0.47

$0.51

50 Day Range

MA: $0.71

$0.46

$0.91

52 Week Range

Now: $0.49

$0.44

$1.80

Volume

65,890 shs

Average Volume

157,600 shs

Market Capitalization

$12.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62

Who are the company insiders with the largest holdings of Inhibikase Therapeutics?: Inhibikase Therapeutics' top insider investors include:
Milton H Werner (CEO)
Joseph Frattaroli (CFO)
Learn More about top insider investors at Inhibikase Therapeutics.
Who are the major institutional investors of Inhibikase Therapeutics?: Inhibikase Therapeutics' top institutional investors include:
Renaissance Technologies LLC — 0.49%
Learn More about top institutional investors of Inhibikase Therapeutics stock.
Which major investors are selling Inhibikase Therapeutics stock?: In the last quarter, IKT stock was sold by these institutional investors:
Renaissance Technologies LLC